Dr. Treon is listed by US News & World Report as being in the top 1% of all doctors in the United States for his specialty.
Please visit our main program website:
Bing Center for Waldenstrom's Macroglobulinemia. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.
WM Workshops: Starting with the first International
Workshop for WM in Washington DC in Sept. 2000, worshops have been
held bi-annually, the most recent in August 2014 in
London, UK. These workshops provide a venue for the WM
scientific community to collaborate and share their latest research
with the goal of advancing the knowledge of the genetic basis and
pathogenesis of WM, and the development of theraputics for this
malignancy. To learn more, please visit our WM Workshop Website.
Patient/Physician Summits: Starting with the first summit in Boston in November, 2001, these conferences have provided a valuable opportunity for patients, their families and caregivers to meet face-to-face with the leaders of the WM scientific community. They can learn the latest developments in the research and treatment of WM, and also participate in working sessions and panel discussions. To learn more, please visit our WM Summit Website.
WM Clinical Trials Group: To find a WM specialist in your
area, including information on clinical trials involving WM, please visit our
WM Clinical Trials
MYD88 L265P is a commonly recurring mutation in patients with Waldenström’s macroglobulinemia that can be useful in differentiating Waldenström’s macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features. Click the graphic to download this groundbreaking NEJM publication.
Dedicated to the Discovery of the Cause and Cure of Waldenstrom's Macroglobulinemia
Dr. Steven Treon is the Director of the Bing Center for Waldenstrom's Macroglobulinemia and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.
After earning a doctorate in tumor immunology from Boston University (BU), Dr Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr Treon also served a clinical fellowship in hematology and oncology at Mass General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997.
Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenstrom's macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenstrom's Macroglobulinemia.
Featured News Items
February, 2015: Many WM patients and caregivers have had questions about the pathway that led to the FDA approval of Imbruvica for WM. Please see the following videos of Dr Treon’s interviews on this historic approval which I hope would be able to answer many of your questions. Please Note: These interviews should not be considered an endorsement of Imbruvica or Pharmacyclics Inc. You should consult with your doctor regarding appropriate treatments. For more information, please visit http://www.prnewswire.com/news-releases/us-fda-approves-imbruvica-ibrutinib-for-treatment-of-waldenstroms-macroglobulinemia-wm-300027914.html
October, 2014, London, UK: The 8th International Workshop for Waldenstrom's Macroglobulinemia and Symposium on Advances in Multiple Myeloma was held from August 13-17, 2014 at the Park Plaza Westminster Hotel, in beautiful historic London, UK. The workshop was attended by over 200 scientists and research staff, representing 20 countries. IWWM-8 included 12 sessions with 50 technical presentations, 8 "Great Debates" (4-MM, 4-WM), 38 poster presentations, including a 2-hour poster session with short oral presentations of accepted posters, a special Saturday luncheon lecture by Dr. Shirley D'Sa, and 4 "Task Force" discussions on various topics in WM. Opening & Closing ceremonies included the awarding of the 2014 Robert Kyle award to Dr. Roger Owen, and the 2014 Waldenstrom Award was shared between Drs. Enrica Morra and Morie Gertz.
October 20-23, 2013, Boston, MA: The Bing Center for
Waldenström’s Macroglobulinemia was proud to host a delegation of distinguished
visiting Dutch hematologists, pathologists, and research principle professors;
M.J Kersten MD and Steven Pals MD PhD (Academic Medical Center), Josephine. Vos MD (St Antonius Hospital Nieuwegein), and Drs Monique.Minnema MD PhD and R.
Groen PhD (University Medical Center Utrecht).